share_log

Apollomics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Apollomics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Apollomics | F-3/A：交易註冊聲明（修正）
美股SEC公告 ·  04/19 16:13

Moomoo AI 已提取核心訊息

Apollomics Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The Cayman Islands-based company, with operations in the U.S. and China, is preparing for the potential sale of securities to the public. The registration includes Class A ordinary shares and warrants, with the exact number and price yet to be determined. The securities may be sold from time to time in one or more offerings, and the proceeds are intended for general corporate purposes. This filing allows Apollomics to maintain an effective registration statement, facilitating future securities offerings. The company has not declared any cash dividends on its shares and does not anticipate doing so in the foreseeable future. Apollomics has obtained a 20-year tax concession from the Cayman Islands government, ensuring no tax on profits, income, gains, or appreciations. The company's Class A ordinary shares and warrants are listed on Nasdaq under the symbols 'APLM' and 'APLMW,' respectively.
Apollomics Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The Cayman Islands-based company, with operations in the U.S. and China, is preparing for the potential sale of securities to the public. The registration includes Class A ordinary shares and warrants, with the exact number and price yet to be determined. The securities may be sold from time to time in one or more offerings, and the proceeds are intended for general corporate purposes. This filing allows Apollomics to maintain an effective registration statement, facilitating future securities offerings. The company has not declared any cash dividends on its shares and does not anticipate doing so in the foreseeable future. Apollomics has obtained a 20-year tax concession from the Cayman Islands government, ensuring no tax on profits, income, gains, or appreciations. The company's Class A ordinary shares and warrants are listed on Nasdaq under the symbols 'APLM' and 'APLMW,' respectively.
處於臨床階段的生物製藥公司Apollomics Inc. 已於2024年4月19日向美國證券交易委員會（SEC）提交了其F-3表格註冊聲明的修正案。這家總部位於開曼群島的公司在美國和中國開展業務，正在爲可能向公衆出售證券做準備。註冊包括A類普通股和認股權證，具體數量和價格尚未確定。證券可以不時通過一次或多次發行出售，所得款項用於一般公司用途。該文件允許Apollomics保留有效的註冊聲明，爲未來的證券發行提供便利。該公司尚未宣佈其股票的任何現金分紅，預計在可預見的將來也不會這樣做。Apollomics已獲得開曼群島政府爲期20年的稅收優惠，確保對利潤、收入、收益或增值不徵稅。該公司的A類普通股和認股權證分別在納斯達克上市，代碼分別爲 “APLM” 和 “APLMW”。
處於臨床階段的生物製藥公司Apollomics Inc. 已於2024年4月19日向美國證券交易委員會（SEC）提交了其F-3表格註冊聲明的修正案。這家總部位於開曼群島的公司在美國和中國開展業務，正在爲可能向公衆出售證券做準備。註冊包括A類普通股和認股權證，具體數量和價格尚未確定。證券可以不時通過一次或多次發行出售，所得款項用於一般公司用途。該文件允許Apollomics保留有效的註冊聲明，爲未來的證券發行提供便利。該公司尚未宣佈其股票的任何現金分紅，預計在可預見的將來也不會這樣做。Apollomics已獲得開曼群島政府爲期20年的稅收優惠，確保對利潤、收入、收益或增值不徵稅。該公司的A類普通股和認股權證分別在納斯達克上市，代碼分別爲 “APLM” 和 “APLMW”。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間